Clinical Trials / Research Studies

Desmoid Tumors Relapse / Refractory

Sarcoma Research Studies

< Back to Young Adult Cancer Research Studies Page

Desmoid Tumors Relapse / Refractory

ARST1921: A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery

  • Ages: 12 Months to 18 Years

This phase II trial studies the side effects and how well nirogacestat works in treating patients with desmoid tumors that has grown after at least one form of treatment by mouth or in the vein that cannot be removed by surgery. Nirogacestat may stop the growth of tumor cells by blocking some of the ...More

PEPN2011: Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Ages: 12 Months to 30 Years

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may help ...More